Portfolio company
Kernal Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
Kernal Bio develops selective messenger RNA therapeutics for patients with cancer and autoimmune diseases to enable precise in vivo cell programming.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kerna
This company develops an artificial intelligence platform to design and deliver messenger ribonucleic acid medicines for patients with previously untreatable conditions.
Synthetic biology-powered mRNA therapeutics
The company develops programmable mRNA therapies using synthetic biology genetic circuits to deliver precise treatments for patients with cancer and other complex diseases.
Strand Tx
Strand Tx develops programmable messenger RNA therapeutics for patients with cancer and autoimmune diseases.
CREATE Medicines
The company develops in vivo CAR therapies using an mRNA platform to treat patients with cancer, autoimmune diseases, and fibrosis.
Capstan Therapeutics
Capstan Therapeutics develops in vivo RNA-based therapies for patients with autoimmune diseases and cancers using targeted lipid nanoparticle technology.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Strand Therapeutics
This biotechnology company develops programmable messenger RNA therapies for patients with solid tumours and autoimmune diseases.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.